Dr Reddy's requests USFDA for re-inspection of Duvvada facility in 2018

In November 2015, the USFDA had issued warning letter against 3 of Dr Reddy's facilities, including the Duvvada plant, after its inspection teams found compliance issues

Dr Reddy's Laboratories Limited on Wednesday informed the stock exchanges that the company has received the establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for its formulations manufacturing facility at Duvvada in Visakhapatnam.

But the company was told that the inspection process was not over yet.

"In the cover letter to the EIR, FDA has explained that the inspection has not closed, and the site's status remains unchanged, but that FDA has released the EIR in order to be transparent about its regulatory process. We are planning to request a reinspection in 2018 after further discussion